Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two drugs: - **Rebif (interferon beta-1a):** A biologic immunomodulator used to treat relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. Interferon beta-1a works by modulating the immune response and reducing inflammation in the central nervous system. Its exact mechanism in MS is not fully understood but involves altering cytokine production and immune cell activity. - **Ibuprofen:** A nonsteroidal anti-inflammatory drug (NSAID) commonly used for pain relief, fever reduction, and inflammation control. It acts primarily by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby decreasing prostaglandin synthesis. This combination is not a fixed-dose product but may be used together in clinical practice—ibuprofen is often recommended to help manage flu-like symptoms associated with interferon therapy[2][4]. There are no major direct interactions reported between these two drugs; however, both can affect liver function or blood counts when combined with other medications[6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rebif + ibuprofen.